The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Liraglutide and Renal Outcomes in Type 2 Diabetes
Open accessAbstract
BACKGROUND: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes in patients with type 2 diabetes are unknown. METHODS: We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo. The secondary renal outcome was a composite of new-onset persistent macroalbuminuria, persistent doubling of the serum creatinine level, end-stage renal disease, or death due to renal disease. The risk of renal outcomes was determined with the use of time-to-event analyses with an intention-to-treat approach. Changes in the estimated glomerular filtration rate and albuminuria were also analyzed. RESULTS: A total of 9340 patients underwent randomization, and the median follow-up of the patients was 3.84 years. The renal outcome occurred in fewer participants in the liraglutide group than in the placebo group (268 of 4668 patients vs. 337 of 4672; hazard ratio, 0.78; 95% confidence interval [CI], 0.67 to 0.92; P=0.003). This result was driven primarily by the new onset of persistent macroalbuminuria, which occurred in fewer participants in the liraglutide group than in the placebo group (161 vs. 215 patients; hazard ratio, 0.74; 95% CI, 0.60 to 0.91; P=0.004). The rates of renal adverse events were similar in the liraglutide group and the placebo group (15.1 events and 16.5 events per 1000 patient-years), including the rate of acute kidney injury (7.1 and 6.2 events per 1000 patient-years, respectively). CONCLUSIONS: This prespecified secondary analysis shows that, when added to usual care, liraglutide resulted in lower rates of the development and progression of diabetic kidney disease than placebo. (Funded by Novo Nordisk and the National Institutes of Health; LEADER ClinicalTrials.gov number, NCT01179048 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The LEADER and REWIND trials also report a greater than 20% reduction in the risk of developing new macroalbuminuria, along with favourable trends in other clinically relevant adverse renal outcomes. 26,27”
The cited source says what the claim attributes to it.
In the citing paper
“Glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) have also been shown to improve kidney outcomes (95-100).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [97]
The cited source says what the claim attributes to it.
In the citing paper
“GLP-1 RAs have also been shown to improve kidney outcomes (104-109).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [106]
In the citing paper
“However, the composite kidney outcomes in these trials were evaluated as secondary outcomes, and the reported effects were largely driven by a lower risk of new-onset macroalbuminuria. 23-25”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [24]
In the citing paper
“Treatment with these drugs is in fact associated with a reduced decline in the estimated glomerular filtration rate (eGFR), as well as with a reduction in urinary albumin excretion and in the incidence rate of de novo albuminuria [28,29].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [28]
In the citing paper
“However, these benefits were driven by a lower risk of persistent macroalbuminuria [6,10,13].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationEffects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationStevens, P. E., Levin, A., & for the Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members* (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-11-201306040-00007 · Cited by 3,607
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate
Stevens, L. A., Coresh, J., Greene, T., & Levey, A. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra054415 · Cited by 2,952
Flagged first, then by citations
1 of the 32 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 401–500 of 1,000
Transforming the Care of Patients with Diabetic Kidney Disease
Brosius, F. C., Cherney, D. Z. I., Gee, P. O., Harris, R. C., Kliger, A. S., Tuttle, K. R., & Quaggin, S. E. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.18641120 · Cited by 28
Type 2 diabetes mellitus management in patients with chronic kidney disease: an update
Kleinaki, Z., Kapnisi, S., Theodorelou‐Charitou, S., Nikas, I. P., & Paschou, S. Α. (2020) · HORMONES · doi:10.1007/s42000-020-00212-y · Cited by 27
Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
MacIsaac, R. J., Trevella, P., & Ekinci, E. I. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13609 · Cited by 27
Xu, Z., Yang, S., & Cui, L. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03808-3 · Cited by 27
Obesity and Metabolic Health in CKD
Kovesdy, C. P. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000704 · Cited by 27
Renal Outcomes of Antidiabetic Treatment Options for Type 2 Diabetes—A Proposed MARE Definition
Prischl, F. C., & Wanner, C. (2018) · Kidney International Reports · doi:10.1016/j.ekir.2018.04.008 · Cited by 27
Expert Consensus on Telemedicine Management of Diabetes (2020 Edition)
Zhang, B. (2021) · International Journal of Endocrinology · doi:10.1155/2021/6643491 · Cited by 27
Nyimanu, D., Chapman, F. A., Gallacher, P. J., Kuc, R. E., Williams, T., Newby, D. E., Maguire, J. J., Davenport, A. P., & Dhaun, N. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15446 · Cited by 27
Emulating the GRADE trial using real world data: retrospective comparative effectiveness study
Deng, Y., Polley, E. C., Wallach, J. D., Dhruva, S. S., Herrin, J. S., Quinto, K., Gandotra, C., Crown, W. H., Noseworthy, P. A., Yao, X., et al. (2022) · BMJ · doi:10.1136/bmj-2022-070717 · Cited by 27
Oda, Y., Nishi, H., & Nangaku, M. (2023) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2023.151431 · Cited by 27
Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus
Shin, J. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1171-0 · Cited by 27
Waki, K., Nara, M., Enomoto, S., Mieno, M., Kanda, E., Sankoda, A., Kawai, Y., Miyake, K., Wakui, H., Tsurutani, Y., et al. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01114-8 · Cited by 26
Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease
Jiménez, D. L., Cherney, D. Z. I., Bjornstad, P., Castilla‐Guerra, L., & Miramontes‐González, J. P. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00384.2017 · Cited by 26
Giorgino, F., Caruso, I., Moellmann, J., & Lehrke, M. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154045 · Cited by 26
McKee, A. M., Al-Khazaali, A., & Albert, S. G. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa037 · Cited by 26
Mechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists
Tommerdahl, K. L., Nadeau, K. J., & Bjornstad, P. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.06.001 · Cited by 26
Racial Disparities and Cardiometabolic Risk: New Horizons of Intervention and Prevention
Akam, E. Y., Nuako, A. A., Daniel, A. K., & Stanford, F. C. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01451-6 · Cited by 26
Kushner, P. R., Cavender, M. A., & Mende, C. W. (2022) · Clinical Diabetes · doi:10.2337/cd21-0119 · Cited by 26
Baylan, U., Korn, A., Emmens, R. W., Schalkwijk, C. G., Niessen, H. W. M., Krijnen, P. A. J., & Şimşek, S. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13807 · Cited by 26
Bulum, T. (2022) · Biomedicines · doi:10.3390/biomedicines10102586 · Cited by 26
Wright, L. A.-C., & Hirsch, I. B. (2019) · Diabetic Medicine · doi:10.1111/dme.13941 · Cited by 26
Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes
Libianto, R., Davis, T. M. E., & Ekinci, E. I. (2020) · The Medical Journal of Australia · doi:10.5694/mja2.50472 · Cited by 26
Mosenzon, O., Bain, S. C., Heerspink, H. J. L., Idorn, T., Mann, J. F. E., Persson, F., Pratley, R. E., Rasmussen, S., Rossing, P. R., von Scholten, B. J., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14126 · Cited by 26
Self-citationNovel therapeutic agents for the treatment of diabetic kidney disease
Hartman, R. E., Rao, S., Churchwell, M. D., & Lewis, S. J. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1811231 · Cited by 26
Bae, J. H., Park, E.-G., Kim, S., Kim, S. G., Hahn, S., & Kim, N. H. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2020.912 · Cited by 26
A New Chapter for Diabetic Kidney Disease
de Boer, I. H. (2017) · New England Journal of Medicine · doi:10.1056/nejme1708949 · Cited by 26
Mann, J. F. E., & Muskiet, M. H. A. (2021) · Kidney International · doi:10.1016/j.kint.2020.08.036 · Cited by 25
Self-citationNatale, P., Green, S. C., Tunnicliffe, D. J., Pellegrino, G., Toyama, T., & Strippoli, G. F. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015849.pub2 · Cited by 25
Igel, L. I., Saunders, K. H., & Fins, J. J. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0740-z · Cited by 25
The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes
García-Carro, C., Vergara, A., Agraz, I., Jacobs-Cachá, C., Espinel, E., Serón, D., & Soler, M. J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060864 · Cited by 25
Fitch, A., & Ingersoll, A. B. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1845534 · Cited by 25
Górriz, J. L., Romera, I., Cobo, A., O’Brien, P. D., & Merino-Torres, J. F. (2022) · Diabetes Therapy · doi:10.1007/s13300-021-01198-5 · Cited by 25
Cheng, P., Chen, W., Hou, C. J., Lin, C., Chang, M., Wang, C., Chang, W., Wang, C., Lin, C., Hung, C., et al. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0315 · Cited by 25
Renal outcomes with dipeptidyl peptidase-4 inhibitors
Scheen, A. J., & Delanaye, P. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.07.011 · Cited by 25
Oikonomaki, D., Dounousi, E. C., Duni, Α., Roumeliotis, S. K., & Liakopoulos, V. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108604 · Cited by 25
Aguilar-Ballester, M., Hurtado-Genovés, G., Taberner-Cortés, A., Herrero-Cervera, A., Martínez‐Hervás, S., & Navarro, H. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020660 · Cited by 25
Hsiao, F., Lin, C., Tung, Y., Wu, C.-T., & Chu, P. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109076 · Cited by 25
Sridhar, V. S., Rahman, H. U., & Cherney, D. Z. I. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13965 · Cited by 24
Atualizações sobre os medicamentos da Diretriz Brasileira de Obesidade: uma revisão de literatura
Marcon, G. M., Sanches, A. C. C., & Virtuoso, S. (2022) · Research Society and Development · doi:10.33448/rsd-v11i4.27139 · Cited by 24
Liraglutide Promotes Diabetic Wound Healing via Myo1c/Dock5
Zhang, Q., Zhang, C., Kang, C., Zhu, J., He, Q., Li, H., Tong, Q., Wang, M., Zhang, L., Xiong, X., et al. (2024) · Advanced Science · doi:10.1002/advs.202405987 · Cited by 24
Mann, J. F. E., Marx, N., Deanfield, J. E., Emerson, S. S., Inzucchi, S. E., McGuire, D. K., Mulvagh, S. L., Pop-Busui, R., Poulter, N. R., Engelmann, M. D. M., et al. (2025) · Diabetes Care · doi:10.2337/dc25-1080 · Cited by 24
Self-citationBoye, K. S., Botros, F. T., Haupt, A., Woodward, B., & Lage, M. J. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0377-5 · Cited by 24
Kugler, A. J., & Thiman, M. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s134960 · Cited by 24
Caparrotta, T. M., Templeton, J. B., Clay, T. A., Wild, S. H., Reynolds, R. M., Webb, D. J., & Colhoun, H. M. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01021-1 · Cited by 24
Rossing, P. R. (2022) · Kidney International Supplements · doi:10.1016/j.kisu.2021.11.005 · Cited by 24
TODAY Study Group, Bjornstad, P., ghormli, L. K. E., Hughan, K. S., Laffel, L. M., Nadeau, K. J., Rayas, M. S., Tesfaldet, B., Tollefsen, S. E., Willi, S. M., et al. (2021) · Diabetes Care · doi:10.2337/dc21-1085 · Cited by 24
Cen, J., Han, Y. Y., Liu, Y., & Hu, H. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.916704 · Cited by 24
Managing thrombotic risk in patients with diabetes
Camm, A. J., Sabbour, H. M., Schnell, O., Summaria, F., & Verma, A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01581-x · Cited by 24
Merza, N., Akram, M., Mengal, A., Rashid, A. M., Mahboob, A., Faryad, M., Fatima, Z., Ahmed, M., & Ansari, S. A. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101602 · Cited by 24
Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
Berman, C., Vidmar, A. P., & Chao, L. C. (2023) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2023.19.1.38 · Cited by 24
Small GTPase Arf6 regulates diabetes‐induced cholesterol accumulation in podocytes
Hu, J., Yang, Q., Chen, Z., Liang, W., Feng, J., & Ding, G. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28924 · Cited by 24
Patoulias, D., Stavropoulos, K., Imprialos, K. P., Katsimardou, A., Kalogirou, M., Koutsampasopoulos, K., Zografou, I., Papadopoulos, C. E., Karagiannis, A. I., & Doumas, M. N. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107927 · Cited by 24
Sabouret, P. F., Galati, G., Angoulvant, D., Андреевна, Г. О., Castelletti, S., Pathak, A., Metra, M., & Margonato, A. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa051 · Cited by 24
Advances in the management of diabetes: therapies for type 2 diabetes
Tsoutsouki, J., Wunna, W., Chowdhury, A., & Chowdhury, T. A. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-137404 · Cited by 24
Martin, W. P., Bauer, J., Coleman, J., Dellatorre‐Teixeira, L., Reeve, J. L., Twomey, P. J., Docherty, N. G., O’Riordan, A., Watson, A. J., le Roux, C. W., et al. (2020) · Clinical Obesity · doi:10.1111/cob.12402 · Cited by 24
ASIAN PACIFIC SOCIETY OF NEPHROLOGY CLINICAL PRACTICE GUIDELINE ON DIABETIC KIDNEY DISEASE
Liew, A., Bavanandan, S., Prasad, N., Wong, M. G., Chang, J. M., Eiam‐Ong, S., Hao, C., Lim, C. Y., Lim, S. K., Oh, K., et al. (2020) · Nephrology · doi:10.1111/nep.13785 · Cited by 24
Structural Lesions on Kidney Biopsy in Youth-Onset and Adult-Onset Type 2 Diabetes
Looker, H. C., Pyle, L., Vigers, T., Severn, C., Saulnier, P., Najafian, B., Mauer, M. S., Nelson, R. G., & Bjornstad, P. (2022) · Diabetes Care · doi:10.2337/dc21-1688 · Cited by 24
Goldenberg, R. M., Ahooja, V., Clemens, K. K., Gilbert, J. D., Poddar, M., & Verma, S. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.09.005 · Cited by 23
Jiao, X., Peng, P., Zhang, Q., & Shen, Y. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01319-x · Cited by 23
Okuma, H., & Tsuchiya, K. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108699 · Cited by 23
Targeting inflammation to reduce ASCVD in type 2 diabetes
Jialal, I., & Chaudhuri, A. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.11.001 · Cited by 23
Recent advances in new-onset diabetes mellitus after kidney transplantation
Montada-Atin, T., & Prasad, G. V. R. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i5.541 · Cited by 23
Schechter, M., Cohen, C. M., Fishkin, A., Rozenberg, A., Yanuv, I., Sehtman-Shachar, D. R., Chodick, G., Clark, A., Abrahamsen, T. J., Lawson, J., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01829-0 · Cited by 23
Harrison, T. G., Tam‐Tham, H., Hemmelgarn, B. R., Elliott, M. J., James, M. T., Ronksley, P. E., & Jun, M. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.10.014 · Cited by 23
Landgraf, R., Kellerer, M., Fach, E.-M., Gallwitz, B., Hamann, A., Joost, H., Klein, H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., et al. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-115964 · Cited by 23
Terauchi, Y., Utsunomiya, K., Yasui, A., Seki, T., Cheng, G., Shiki, K., & Lee, J. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0604-8 · Cited by 23
Muskiet, M. H. A., Bunck, M. C. M., Heine, R. J., Cornér, A., Yki‐Järvinen, H., Eliasson, B., Joles, J. A., Diamant, M., Tonneijck, L., & van Raalte, D. H. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.05.001 · Cited by 23
Ramos, A. M., Fernández‐Fernández, B., Pérez-Gómez, M. V., Julio, S. M. C., Sánchez-Niño, M. D., Sanz, A. B., Ruiz‐Ortega, M., & Ortíz, A. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1690450 · Cited by 23
Cardioprotective diabetes drugs: what cardiologists need to know
Brown, J. M., & Everett, B. M. (2019) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000181 · Cited by 23
Abdelhafiz, A. H. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00773-y · Cited by 23
Xiao, S., Yang, Y., Liu, Y., & Zhu, J. (2021) · Journal of Diabetes Research · doi:10.1155/2021/8873956 · Cited by 23
Khunti, K., Gavin, J. R., Boulton, A. J. M., Blickstead, R., McGill, M. J., Ceriello, A., Raz, I., SADIKOT, S. M., Wood, D. A., Cos, X., et al. (2018) · Primary care diabetes · doi:10.1016/j.pcd.2018.04.003 · Cited by 23
Gill, L. A., & Mackey, S. (2021) · Journal of Women s Health · doi:10.1089/jwh.2020.8683 · Cited by 22
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., & Siegel, E. G. (2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-1193-3793 · Cited by 22
González‐González, J. G., Solís, R. C., González-Colmenero, A. D., Raygoza-Cortez, K., Moreno-Peña, P. J., Sánchez, A. L., McCoy, R. G., Ospina, N. S., Maraka, S., Brito, J. P., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109821 · Cited by 22
Exploring molecular targets in diabetic kidney disease
Maruno, S., Tanaka, T., & Nangaku, M. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.21.251 · Cited by 22
Recent advances in the treatment of patients with obesity and chronic kidney disease
Wahab, R. A., COHEN, R. V., & le Roux, C. W. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2203517 · Cited by 22
Bertoluci, M. C., Júnior, W. S. D. S., Valente, F., Araujo, L. R., Lyra, R., de Castro, J. J., Raposo, J. F., Miranda, P. A. C., Boguszewski, C. L., Hohl, A., et al. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01121-x · Cited by 22
Emerging role of antidiabetic drugs in cardiorenal protection
Fu, W.-J., Huo, J., Mao, Z., Pan, S.-K., Liu, D., Liu, Z., Wu, P., & Gao, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1349069 · Cited by 22
Potential kidney protective effects of glucagon‐like peptide‐1 receptor agonists
Trevella, P., Ekinci, E. I., & MacIsaac, R. J. (2024) · Nephrology · doi:10.1111/nep.14336 · Cited by 22
Chiang, C., Lin, S.-Y., Lin, T., Wang, T., Yeh, H., Chen, J., Tsai, C., Hung, Y.-J., Li, Y., Liu, P., et al. (2018) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2018.01.001 · Cited by 22
Novel Therapies for Kidney Disease in People With Diabetes
Khurana, N., James, S., Coughlan, M. T., MacIsaac, R. J., & Ekinci, E. I. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab639 · Cited by 22
Youssef, N., Noureldein, M. H., Njeim, R., Ghadieh, H. E., Harb, F., Azar, S. T., Farès, N., & Eid, A. A. (2021) · Biomedicines · doi:10.3390/biomedicines9101360 · Cited by 22
Management of post-transplant diabetes mellitus: an opportunity for novel therapeutics
Montero, N., Oliveras, L., Soler, M. J., & Cruzado, J. M. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab131 · Cited by 22
Mise, K., Imamura, M., Yamaguchi, S., Teshigawara, S., Tone, A., Uchida, H. A., Eguchi, J., Nakatsuka, A., Ogawa, D., Yoshida, M., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0030 · Cited by 22
Reed, J., Bain, S. C., & Kanamarlapudi, V. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s415934 · Cited by 21
Zhou, X., Fan, Q.-Y., Targher, G., Byrne, C. D., Chen, Q., Shapiro, M. D., Dong, Y.-X., Sung, K., Lip, G. Y. H., Lazarus, J. V., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3193-9 · Cited by 21
Renal Hemodynamic Function and RAAS Activation Over the Natural History of Type 1 Diabetes
Lytvyn, Y., Bjornstad, P., Lovshin, J. A., Boulet, G., Farooqi, M. A., LAI, V. S., TSE, J. M., Cham, L., Lovblom, L. E., Weisman, A., et al. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.12.034 · Cited by 21
Cardiorenal Protection in Diabetic Kidney Disease
Lee, J. F., Berzan, E., Sridhar, V. S., Odutayo, A., & Cherney, D. Z. I. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.987 · Cited by 21
Re-thinking diabetic nephropathy: Microalbuminuria is just a piece of the diagnostic puzzle
Ceccarelli, D. C., Paleari, R., Solerte, B., & Mosca, A. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.11.009 · Cited by 21
Even high normal blood pressure affects live birth rate in women undergoing fresh embryo transfer
Chen, H., Zhang, X., Cai, S., Li, J., Tang, S., Hocher, C., Rösing, B., Hu, L., Lin, G., Gong, F., et al. (2022) · Human Reproduction · doi:10.1093/humrep/deac201 · Cited by 21
Liu, X., Ge, M., Zhai, X., Xiao, Y., Zhang, Y., Xu, Z., Zhou, Z., Mei, Z., & Yang, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1009571 · Cited by 21
Ngoc, N. B., Nguyen, L., Mital, S., Bugden, S., & Nguyen, H. V. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15009 · Cited by 21
Peng, Z., Yang, C.-T., Lin, W., Yao, W., Ou, H., & Kuo, S. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01991-5 · Cited by 21
Anti-obesity pharmacotherapy in adults with chronic kidney disease
Taber-Hight, E., Gilmore, A. C., & Friedman, A. N. (2023) · Kidney International · doi:10.1016/j.kint.2023.10.014 · Cited by 21
Gong, X., Zeng, X., & Fu, P. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1320627 · Cited by 21
Rodriguez‐Valadez, J. M., Tahsin, M., Masharani, U. B., Park, M., Hunink, M. G. M., Yeboah, J., Li, L., Weber, E. S., Berkalieva, A., Avezaat, L., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032463 · Cited by 21
Bouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14202 · Cited by 21
Exploring the Cardiorenal Benefits of SGLT2i: A Comprehensive Review
Cersosimo, A., Drera, A., Adamo, M., Metra, M., & Vizzardi, E. (2024) · Kidney and Dialysis · doi:10.3390/kidneydial4040016 · Cited by 21
Novel avenues for drug discovery in diabetic kidney disease
Breyer, M. D., & Kretzler, M. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1398731 · Cited by 21
Metadata
- Authors
- Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B.
- Affiliations
- Mount Sinai Hospital (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-08-31
- Volume
- 377
- Issue
- 9
- Pages
- 839-848
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2752707491
- Semantic Scholar
- e3932087f500b455476965939bdced15360eb028
- Cited by
- 1,253
- References
- 32
- Citations by year
- 2026: 99 · 2025: 116 · 2024: 121 · 2023: 131 · 2022: 134 · 2021: 161 · 2020: 180 · 2019: 139 · 2018: 152 · 2017: 20
- FWCI
- 106.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Americanae (AECID Library) (publishedVersion, other-oa)
- ResearchOnline - JCU (James Cook University) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
- Funders
- Novo Nordisk
- National Institutes of Health (UL1TR001111)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- liraglutide, type 2 diabetes, renal outcomes, diabetic nephropathy, macroalbuminuria, end-stage renal disease, acute kidney injury, glucagon-like peptide-1 analogues, albuminuria, estimated glomerular filtration rate, cardiovascular risk, renal adverse effects, LEADER trial, cardiovascular outcomes, serum creatinine doubling, usual care
- MeSH terms
- Liraglutide, Aged, Albuminuria, Creatinine, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Follow-Up Studies, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Kidney Failure, Chronic, Male, Middle Aged, Glucagon-Like Peptide 1, Intention to Treat Analysis, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
